Elabela/toddler: New peptide with a promising future in cancer diagnostic and therapy

Benjamin Liet; Nicolas Nys; Geraldine Siegfried

doi:10.1016/j.bbamcr.2021.119065

Elabela/toddler: New peptide with a promising future in cancer diagnostic and therapy

Biochim Biophys Acta Mol Cell Res. 2021 Aug;1868(9):119065. doi: 10.1016/j.bbamcr.2021.119065. Epub 2021 Jun 4.

Authors

Benjamin Liet¹, Nicolas Nys¹, Geraldine Siegfried²

Affiliations

¹ Institut National de la Santé et de la Recherche Médicale U1029 LAMC, F-33400 Talence, France; Université de Bordeaux F-33400, Talence, France.
² Institut National de la Santé et de la Recherche Médicale U1029 LAMC, F-33400 Talence, France; Université de Bordeaux F-33400, Talence, France. Electronic address: geraldine.siegfried@inserm.fr.

PMID: 34090960
DOI: 10.1016/j.bbamcr.2021.119065

Abstract

Elabela/toddler is the second endogenous ligand recently identified after Apelin, that binds to the G protein-coupled receptor APJ. Elabela is a 54-amino acid peptide initially identified in fish and human genomes and classified as noncoding. This precursor can be cleaved to shorter sequences (32, 21, and 11 amino acids), which bind and activate APJ, and can be blocked by APJ antagonists. Contrary to Apelin and APJ, widely distributed in organs and tissues, Elabela expression is more restricted, and different studies have revealed the potential role of Elabela in cancers. This review summarizes the current studies focusing on the role of Elabela in different cancers.

Keywords: APJ; Cancer; ELABELA; Therapeutic targets.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Humans
Ligands
Neoplasms* / diagnosis
Neoplasms* / therapy
Peptide Hormones / chemistry*
Peptide Hormones / genetics
Peptide Hormones / metabolism*

Substances

APELA protein, human
Ligands
Peptide Hormones